This article is more than 5 years old. Information may no longer be current.

Antibiotic may combat multidrug-resistant organisms, studies show

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Two studies presented at the Association for Research in Vision and Ophthalmology meeting demonstrate that besifloxacin may offer potent activity and high rates of eradication against multidrug-resistant organisms responsible for many eye infections, Bausch + Lomb reported in a news release.

The Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study, sponsored by Bausch + Lomb and now in its fourth year, monitors common antibiotics for their potency against ocular pathogens.

In the 2011 ARMOR findings, besifloxacin demonstrated in vitro potency similar to that of vancomycin, the release said.

In a separate study, besifloxacin suspension 0.6% demonstrated high rates of eradication of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE), according to the release.

In 49 patients with bacterial conjunctivitis who were treated with besifloxacin, 75% of MRSA and 84% of MRSE infections were eradicated within 3 to 5 days, the release said. Seven to 9 days after treatment, the rates increased to 83% and 89%, respectively.